|
Follicular Variant Thyroid Gland Papillary Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the identified APLP2, RRM2, and PRC1 signature could be useful for distinguishing between benign (FA) and malignant (FTC and FVPTC) tumors of the thyroid follicular epithelium.
|
27796194 |
2017 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We determined that RRM2 and COL3A1 were increased and directly correlated with glioma grade, while SH3GL2 and SNAP91 were decreased in GBM and inversely correlated with glioma grade.
|
27655637 |
2016 |
|
MYELODYSPLASTIC SYNDROME
|
0.010 |
Biomarker
|
group |
BEFREE |
We determined the expression levels of genes involved in AZA metabolism: UCK1, UCK2, DCK, hENT1, RRM1 and RRM2 using quantitative PCR in samples from 57 patients with MDS who received AZA.
|
24192812 |
2014 |
|
estrogen receptor-negative breast cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
RRM2 appears to be a promising prognostic biomarker and therapeutic target for ER-negative breast cancer patients.
|
25213022 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RRM1 and RRM2 mRNA expression levels were significantly correlated with each other in both CEU and YRI lymphoblast cell lines, and in leukemic blasts from acute myeloid leukemia (AML) patients (AML97, n = 89; AML02, n = 187).
|
24024897 |
2013 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
|
23719266 |
2013 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Cysteine oxidation of the two RNA recognition motifs (RRM1 and RRM2) of TDP-43, a multi-domain protein involved in neurodegenerative diseases, results in loss of function and accumulation of insoluble aggregates under both in vitro and in vivo conditions.
|
23384725 |
2013 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Multivariate logistic analysis indicated that the adjusted ORs (odds ratios) of RRM2-high for distant metastases were 2.06 [95% CI (confidence interval), 1.01-4.30] and 5.89 (95% CI, 1.51-39.13) in the COH and ZJU sets respectively.
|
23113760 |
2013 |
|
Frontotemporal Lobar Degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence suggests that pathogenic TAR DNA-binding protein (TDP)-43 fragments contain a partial RNA-recognition motif domain 2 (RRM2) in amyotrophic lateral sclerosis (ALS)/frontotemporal lobar degeneration.
|
23300771 |
2012 |
|
GRN-related frontotemporal dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence suggests that pathogenic TAR DNA-binding protein (TDP)-43 fragments contain a partial RNA-recognition motif domain 2 (RRM2) in amyotrophic lateral sclerosis (ALS)/frontotemporal lobar degeneration.
|
23300771 |
2012 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Positive RRM2 staining was observed in none of 14 examples of non-neoplastic urothelium, none of four low-grade urothelial carcinoma (UC), 69 of 83 (83%) high-grade UC, three of three (100%) squamous cell carcinoma and 12 of 13 (92%) lymph node metastasis of UC.
|
21166702 |
2010 |
|
Carcinoma, Transitional Cell
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RRM2 overexpression was associated significantly with muscularis propria invasion in UC patients who had undergone radical cystectomy (P=0.005).
|
21166702 |
2010 |
|
Cystitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Positive RRM2 staining was found in one of 15 (6.7%) cystitis with reactive atypia cases and in 24 of 25 (96%) CIS cases.
|
21166702 |
2010 |
|
Hepatitis
|
0.010 |
Biomarker
|
group |
BEFREE |
Our integrative result showed that RRM2 phosphoprotein cluster of HCC contained both in human no-tumor hepatitis/cirrhotic liver tissues and HCC terms of phosphoprotein (with RRM2) and cell cycle (without RRM2), only in HCC terms of cell-cell signaling, cell projection part, glycoprotein, cell projection, cell adhesion, biological adhesion, integral to plasma membrane, plasma membrane, kinase and phosphorus metabolic process (without RRM2), and none in HCC terms of cell death (without RRM2) and ion binding (with RRM2) compared with human no-tumor hepatitis/cirrhotic liver tissues, all the condition is vital to invasion of HCC.
|
20798514 |
2010 |
|
Hepatitis A
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our integrative result showed that RRM2 phosphoprotein cluster of HCC contained both in human no-tumor hepatitis/cirrhotic liver tissues and HCC terms of phosphoprotein (with RRM2) and cell cycle (without RRM2), only in HCC terms of cell-cell signaling, cell projection part, glycoprotein, cell projection, cell adhesion, biological adhesion, integral to plasma membrane, plasma membrane, kinase and phosphorus metabolic process (without RRM2), and none in HCC terms of cell death (without RRM2) and ion binding (with RRM2) compared with human no-tumor hepatitis/cirrhotic liver tissues, all the condition is vital to invasion of HCC.
|
20798514 |
2010 |
|
Transitional cell carcinoma in situ
|
0.010 |
Biomarker
|
disease |
BEFREE |
Positive RRM2 staining was found in one of 15 (6.7%) cystitis with reactive atypia cases and in 24 of 25 (96%) CIS cases.
|
21166702 |
2010 |
|
Infective cystitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Positive RRM2 staining was found in one of 15 (6.7%) cystitis with reactive atypia cases and in 24 of 25 (96%) CIS cases.
|
21166702 |
2010 |
|
Urothelial Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RRM2 overexpression was associated significantly with muscularis propria invasion in UC patients who had undergone radical cystectomy (P=0.005).
|
21166702 |
2010 |
|
Advanced Bile Duct Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
RRM1 and RRM2 protein strongly correlated with the IC(50) value for gemcitabine in BTC cell lines (R=0.935, 0.771, respectively).
|
20811706 |
2010 |
|
Pancreatic carcinoma non-resectable
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this prospective study, we hypothesized that RRM2 expression in PC biopsy specimens would be a significant predictor of outcome.
|
17530364 |
2007 |
|
Carcinoma breast stage IV
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In order to assess target down-regulation by GTI-2040, RRM2 mRNA expression levels were analyzed in pre- and post-treatment samples from a phase II clinical trial of GTI-2040 combined with capecitabine in patients with metastatic breast cancer.
|
16596201 |
2006 |
|
Hydatidiform Mole
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Thymidine kinase-1 (TK-1) and small subunit ribonucleotide reductase (RRM-2) were overexpressed in HM, JAR, and JEG-3.
|
15361213 |
2004 |
|
Endometrial Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Eventually, C2orf48, LINC00483, and AC110491.1 were identified as three key lncRNAs in EC.
|
31056798 |
2019 |
|
Endometrial Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS Our study showed that the lncRNAs C2orf48 and LINC00261 might be key regulators of uterine corpus endometrial carcinoma and might serve as prognostic indicators.
|
31650984 |
2019 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Six hub genes (DTL, DLGAP5, KIF15, NUSAP1, RRM2, and TOP2A) present promising predictive value for the development and prognosis of OC and may be used as candidate targets for diagnosis and treatment of OC.
|
31729978 |
2019 |